This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock VACC vs. DERM, EPRX, CYBN, NKTX, NKTR, ATOS, KRRO, ALDX, ACRS, and GLSIShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Journey Medical (DERM), Eupraxia Pharmaceuticals (EPRX), Cybin (CYBN), Nkarta (NKTX), Nektar Therapeutics (NKTR), Atossa Therapeutics (ATOS), Korro Bio (KRRO), Aldeyra Therapeutics (ALDX), Aclaris Therapeutics (ACRS), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical preparations" industry. Vaccitech vs. Journey Medical Eupraxia Pharmaceuticals Cybin Nkarta Nektar Therapeutics Atossa Therapeutics Korro Bio Aldeyra Therapeutics Aclaris Therapeutics Greenwich LifeSciences Journey Medical (NASDAQ:DERM) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings. Do institutionals and insiders believe in DERM or VACC? 7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 26.1% of Vaccitech shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by company insiders. Comparatively, 6.0% of Vaccitech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor DERM or VACC? Vaccitech received 10 more outperform votes than Journey Medical when rated by MarketBeat users. However, 87.50% of users gave Journey Medical an outperform vote while only 70.83% of users gave Vaccitech an outperform vote. CompanyUnderperformOutperformJourney MedicalOutperform Votes787.50% Underperform Votes112.50%VaccitechOutperform Votes1770.83% Underperform Votes729.17% Do analysts recommend DERM or VACC? Journey Medical presently has a consensus target price of $9.88, suggesting a potential upside of 40.97%. Given Journey Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Journey Medical is more favorable than Vaccitech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor DERM or VACC? In the previous week, Journey Medical had 9 more articles in the media than Vaccitech. MarketBeat recorded 9 mentions for Journey Medical and 0 mentions for Vaccitech. Vaccitech's average media sentiment score of 0.00 beat Journey Medical's score of -0.16 indicating that Vaccitech is being referred to more favorably in the news media. Company Overall Sentiment Journey Medical Neutral Vaccitech Neutral Which has more risk & volatility, DERM or VACC? Journey Medical has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Is DERM or VACC more profitable? Journey Medical has a net margin of -31.74% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Journey Medical's return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-31.74% -132.10% -26.90% Vaccitech -409.18%-23.41%-20.85% Which has stronger valuation & earnings, DERM or VACC? Vaccitech has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Vaccitech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.24M2.88-$3.85M-$0.39-17.96Vaccitech$13.42M2.33$5.34M-$1.43-0.57 SummaryJourney Medical beats Vaccitech on 12 of the 19 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.22M$6.47B$5.31B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-0.578.5926.6919.58Price / Sales2.33257.78393.58120.51Price / Cash19.3065.8538.2534.62Price / Book0.126.396.744.47Net Income$5.34M$143.98M$3.23B$248.32M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$0.81-2.3%N/A-61.5%$31.22M$13.42M-0.5733Gap UpDERMJourney Medical1.8668 of 5 stars$6.02-4.7%$9.88+64.0%+92.1%$139.09M$56.13M-6.4090Gap UpEPRXEupraxia Pharmaceuticals2.1186 of 5 stars$3.82-1.3%$10.50+174.9%+28.3%$136.94MN/A-5.3129CYBNCybin2.7362 of 5 stars$6.32-4.1%$86.00+1,260.8%N/A$135.74MN/A-1.4450Positive NewsNKTXNkarta1.9655 of 5 stars$1.90-2.1%$14.83+680.7%-74.6%$134.82MN/A-1.01140Gap DownNKTRNektar Therapeutics4.1412 of 5 stars$0.71+0.3%$4.50+532.0%-62.3%$132.51M$98.43M-0.85220Gap DownATOSAtossa Therapeutics2.0432 of 5 stars$1.02+14.0%$7.13+602.0%-43.1%$131.11MN/A-4.618Gap DownHigh Trading VolumeKRROKorro Bio1.9496 of 5 stars$13.68-12.0%$104.63+664.8%-70.5%$128.47M$4.82M-1.4570Gap DownALDXAldeyra Therapeutics2.2329 of 5 stars$2.13+2.4%$9.50+346.0%-41.9%$127.58MN/A-2.2715Trending NewsAnalyst UpgradeAnalyst RevisionACRSAclaris Therapeutics2.8728 of 5 stars$1.17-4.5%$10.00+758.4%+9.6%$126.15M$18.72M-2.24100Positive NewsGLSIGreenwich LifeSciences1.1977 of 5 stars$9.49-2.1%$39.00+311.0%-27.4%$125.97MN/A-11.863Earnings Report Related Companies and Tools Related Companies Journey Medical Competitors Eupraxia Pharmaceuticals Competitors Cybin Competitors Nkarta Competitors Nektar Therapeutics Competitors Atossa Therapeutics Competitors Korro Bio Competitors Aldeyra Therapeutics Competitors Aclaris Therapeutics Competitors Greenwich LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VACC Stock Free VACC Stock Alerts